<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://media.rss.com/style.xsl"?>
<rss xmlns:podcast="https://podcastindex.org/namespace/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:psc="http://podlove.org/simple-chapters" xmlns:atom="http://www.w3.org/2005/Atom" xml:lang="en" version="2.0">
  <channel>
    <title><![CDATA[mygmptraining]]></title>
    <link>https://rss.com/podcasts/gxptraining</link>
    <atom:link href="https://media.rss.com/gxptraining/feed.xml" rel="self" type="application/rss+xml"/>
    <atom:link rel="hub" href="https://pubsubhubbub.appspot.com/"/>
    <description><![CDATA[<p>Regulations tell you <em>what</em> to do, but 40 years of experience tells you <em>how</em> to do it right the first time. Join us on <strong>mygmptraining </strong>as we pull back the curtain on FDA compliance and quality systems. Whether you’re a seasoned Quality Director or a newcomer to the lab, we provide the insights, pitfalls, and "war stories" necessary to build a culture of compliance that stands up to any audit.</p><p>#GxPTraining #PharmaCompliance #QualitySystems #Biologics #RegulatoryAffairs #FDACompliance #QualityAssurance #PharmaceuticalManufacturing #LifeSciences #GMP #GLP #GCP #PharmaExpert #QualityManagement #AuditReady #BiotechCompliance</p>]]></description>
    <generator>RSS.com 2026.401.141116</generator>
    <lastBuildDate>Wed, 08 Apr 2026 17:22:01 GMT</lastBuildDate>
    <language>en</language>
    <copyright><![CDATA[All rights reserved. 2026]]></copyright>
    <itunes:image href="https://media.rss.com/gxptraining/20260131_020102_de73d0c71496185a18507b959a3397b4.jpg"/>
    <podcast:guid>5ff20433-2fc6-5854-854f-b97880aed00c</podcast:guid>
    <image>
      <url>https://media.rss.com/gxptraining/20260131_020102_de73d0c71496185a18507b959a3397b4.jpg</url>
      <title>mygmptraining</title>
      <link>https://rss.com/podcasts/gxptraining</link>
    </image>
    <podcast:locked>yes</podcast:locked>
    <podcast:license>All rights reserved. 2026</podcast:license>
    <itunes:author>Shamik (Sam) Pandit</itunes:author>
    <itunes:owner>
      <itunes:name>Shamik (Sam) Pandit</itunes:name>
    </itunes:owner>
    <itunes:explicit>false</itunes:explicit>
    <itunes:type>episodic</itunes:type>
    <itunes:category text="Business">
      <itunes:category text="Management"/>
    </itunes:category>
    <itunes:category text="Education">
      <itunes:category text="Courses"/>
    </itunes:category>
    <podcast:medium>podcast</podcast:medium>
    <podcast:location rel="creator" geo="geo:39.7837304,-100.445882" osm="R148838" country="us">United States, USA</podcast:location>
    <podcast:txt purpose="ai-content">true</podcast:txt>
    <item>
      <title><![CDATA[High Purity Water System]]></title>
      <itunes:title><![CDATA[High Purity Water System]]></itunes:title>
      <description><![CDATA[<p>This episode of the <strong>Deep Dive</strong> podcast navigates the complex regulatory and engineering landscape of <strong>pharmaceutical water systems</strong>, using the <strong>FDA’s July 1993 Inspection Guide</strong> as a foundational roadmap.</p><p><strong>WFI (Water for Injection):</strong> Required for parenteral (injectable) drugs, WFI must be free of <strong>pyrogens</strong>, specifically <strong>endotoxins</strong>—the structural remnants of dead gram-negative bacteria that can cause severe immune responses like anaphylactic shock. It must undergo phase-change (distillation) or reverse osmosis to ensure the absence of endotoxins.</p><p><strong>Purified Water:</strong> High-purity water used for non-sterile applications like oral medications and topicals, requiring stringent microbial control but lower endotoxin thresholds than WFI.</p><p><strong>Process/Potable Water:</strong> The baseline for manufacturing, though vulnerable to environmental contaminants like agricultural runoff.</p><p><strong>Hot vs. Cold Systems:</strong> Hot systems (65–80°C) are self-sanitizing but expensive, while cold systems are prone to <strong>biofilms</strong>—microscopic "coral reefs" of bacteria protected by a slimy polymer matrix.</p><p><strong>Mechanical Vulnerabilities:</strong> The dangers of <strong>dead legs</strong> (unused piping), stagnant water in pump housings, and microscopic crevices in threaded fittings.</p><p><strong>Phase 1 &amp; 2:</strong> Developing and testing Standard Operating Procedures (SOPs) through daily sampling for several weeks.</p><p><strong>Phase 3:</strong> A full year of routine testing to prove the system can handle <strong>seasonality</strong>, such as spring algae blooms or sudden infrastructure shocks like fire department hydrant use.</p><p><strong>The "Action Limit":</strong> Understanding that a spike in data mandates an immediate documented investigation into the root cause, rather than simply "testing into compliance".</p><p><strong>Pyrogens/Endotoxins:</strong> Structural components of dead gram-negative bacteria that can cause severe fevers or anaphylactic shock if they enter the bloodstream.</p><p><strong>LAL (Limulus Amebocyte Lysate) Test:</strong> A biological assay using horseshoe crab blood enzymes to detect and quantify trace amounts of endotoxins.</p><p><strong>Biofilm:</strong> A resilient, microscopic "coral reef" of bacteria that adheres to pipe walls and protects itself with a slimy polymer matrix, making it resistant to standard chemical flushes.</p><p><strong>Dead Leg:</strong> Any unused or stagnant portion of piping where water does not circulate, creating a primary breeding ground for microbial growth.</p><p><strong>Positive Pressure Differential:</strong> An engineering strategy where clean water is kept at a higher pressure than dirty cooling water to ensure that any leaks push clean water out rather than sucking contaminants in.</p><p><strong>SOP (Standard Operating Procedure):</strong> Detailed, mandatory instructions for tasks like valve sequencing or pipe flushing; a failure to follow these can inadvertently suck non-sterile air into a clean system.</p><p><strong>Action Limit:</strong> A specific microbial threshold (e.g., less than 10 CFU per 100ml for WFI) that, if exceeded, requires a documented investigation into the system's root failure.</p><p><strong>Phase 3 Validation:</strong> A full year of routine testing required to prove a system can maintain control across all four seasons and environmental shifts.</p>]]></description>
      <link>https://rss.com/podcasts/gxptraining/2710217</link>
      <enclosure url="https://content.rss.com/episodes/370070/2710217/gxptraining/2026_04_08_16_56_02_10f8d4bf-b3f6-44ce-8ca3-55c31bbff83e.mp3" length="20980433" type="audio/mpeg"/>
      <guid isPermaLink="false">c95b26aa-5a5a-4240-a6df-485c929b6db6</guid>
      <itunes:duration>1311</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:season>2026</itunes:season>
      <podcast:season>2026</podcast:season>
      <itunes:episode>5</itunes:episode>
      <podcast:episode>5</podcast:episode>
      <itunes:explicit>false</itunes:explicit>
      <pubDate>Wed, 08 Apr 2026 16:56:09 GMT</pubDate>
      <podcast:txt purpose="ai-content">true</podcast:txt>
      <itunes:image href="https://media.rss.com/gxptraining/ep_cover_20260408_040446_82e606d9d52bd3cac2d5fb36f2169d06.jpg"/>
    </item>
    <item>
      <title><![CDATA[21 CFR 211 -Subpart B - Organization and Personnel]]></title>
      <itunes:title><![CDATA[21 CFR 211 -Subpart B - Organization and Personnel]]></itunes:title>
      <description><![CDATA[<p>This presentation outlines the <strong>regulatory requirements</strong> for pharmaceutical <strong>organization and personnel</strong> as defined by <strong>21 CFR Part 211, Subpart B</strong>. It emphasizes the critical role of the <strong>Quality Control Unit</strong>, which possesses the authority to approve or reject all materials and procedures impacting product integrity. The materials specify that <strong>staff and consultants</strong> must be qualified through a blend of education and training while adhering to strict <strong>hygiene and gowning protocols</strong> to prevent contamination. Furthermore, the slides list common <strong>FDA citations</strong>, such as poor supervision and failure to maintain training records, to illustrate the consequences of non-compliance. Ultimately, the course serves as a guide for implementing <strong>cGMP fundamentals</strong> through practical application and rigorous management oversight.</p>]]></description>
      <link>https://rss.com/podcasts/gxptraining/2590577</link>
      <enclosure url="https://content.rss.com/episodes/370070/2590577/gxptraining/2026_03_01_12_05_53_7f1135eb-7d94-41bb-9c92-692c39d012ae.mp3" length="18802029" type="audio/mpeg"/>
      <guid isPermaLink="false">99bb7297-6505-455a-a4f9-785505868066</guid>
      <itunes:duration>1175</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:season>2026</itunes:season>
      <podcast:season>2026</podcast:season>
      <itunes:episode>4</itunes:episode>
      <podcast:episode>4</podcast:episode>
      <itunes:explicit>false</itunes:explicit>
      <pubDate>Sun, 01 Mar 2026 12:06:10 GMT</pubDate>
      <podcast:txt purpose="ai-content">true</podcast:txt>
      <itunes:image href="https://media.rss.com/gxptraining/ep_cover_20260301_120339_7e1659c6d7c4fb35f455eb0132d2d1ea.jpg"/>
    </item>
    <item>
      <title><![CDATA[Obstructing FDA inspections]]></title>
      <itunes:title><![CDATA[Obstructing FDA inspections]]></itunes:title>
      <description><![CDATA[<p>This episode outlines <strong>official FDA guidance</strong> regarding the specific behaviors that constitute the <strong>obstruction of drug or device inspections</strong>. Under federal law, if a facility <strong>delays, denies, limits, or refuses</strong> an inspection, the products manufactured there are legally considered <strong>adulterated</strong>. Prohibited actions include <strong>failing to schedule</strong> pre-announced visits, <strong>withholding records</strong>, and <strong>restricting access</strong> to operational areas or photography. While the agency considers <strong>legitimate justifications</strong> for certain disruptions, such as safety protocols or language barriers, it maintains broad authority to ensure <strong>regulatory compliance</strong>.</p><p></p><p>#FDA #RegulatoryCompliance #FDAInspection #Pharma #MedicalDevices #FDALaw #QualityAssurance #AuditReady #LifeSciences #Compliance</p>]]></description>
      <link>https://rss.com/podcasts/gxptraining/2539265</link>
      <enclosure url="https://content.rss.com/episodes/370070/2539265/gxptraining/2026_02_10_12_34_51_de8edac0-55f8-4dfc-965f-f126325c82b3.mp3" length="14510007" type="audio/mpeg"/>
      <guid isPermaLink="false">9982711e-499b-49ee-8cd4-21782002e885</guid>
      <itunes:duration>906</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:season>2026</itunes:season>
      <podcast:season>2026</podcast:season>
      <itunes:episode>3</itunes:episode>
      <podcast:episode>3</podcast:episode>
      <itunes:explicit>false</itunes:explicit>
      <pubDate>Tue, 10 Feb 2026 12:40:53 GMT</pubDate>
      <itunes:image href="https://media.rss.com/gxptraining/ep_cover_20260210_120240_57640a7007465c5be21a235f1f9ad59c.png"/>
    </item>
    <item>
      <title><![CDATA[Process Validation - A Science based approach for Pharmaceutical Quality Assurance]]></title>
      <itunes:title><![CDATA[Process Validation - A Science based approach for Pharmaceutical Quality Assurance]]></itunes:title>
      <description><![CDATA[<p>This podcast outlines the essential standards for <strong>process validation</strong> within the pharmaceutical and biologics industries. It establishes a <strong>three-stage lifecycle approach</strong> that includes <strong>process design</strong>, <strong>process qualification</strong>, and <strong>continued process verification</strong> to ensure drug quality and consistency. The discussion emphasizes using <strong>scientific evidence</strong> and <strong>risk-based analysis</strong> to maintain manufacturing control from initial development through commercial production. This podcast provide a framework for meeting <strong>Current Good Manufacturing Practice (CGMP)</strong> requirements to guarantee product safety and efficacy.</p><p>#processvalidation #FDA</p>]]></description>
      <link>https://rss.com/podcasts/gxptraining/2535618</link>
      <enclosure url="https://content.rss.com/episodes/370070/2535618/gxptraining/2026_02_09_13_42_27_7cf31f0e-0a2d-4889-8e4a-41b195157180.mp3" length="14038967" type="audio/mpeg"/>
      <guid isPermaLink="false">1248c789-dcea-43ab-aa61-efe4b3448803</guid>
      <itunes:duration>877</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:season>2026</itunes:season>
      <podcast:season>2026</podcast:season>
      <itunes:episode>2</itunes:episode>
      <podcast:episode>2</podcast:episode>
      <itunes:explicit>false</itunes:explicit>
      <pubDate>Mon, 09 Feb 2026 13:42:35 GMT</pubDate>
      <itunes:image href="https://media.rss.com/gxptraining/ep_cover_20260209_010218_9a1c42791a6c72efe2fb333153de3d95.jpg"/>
    </item>
    <item>
      <title><![CDATA[The Case of the Failed Batch]]></title>
      <itunes:title><![CDATA[The Case of the Failed Batch]]></itunes:title>
      <description><![CDATA[<p>This episode talks about the <strong>FDA-mandated guidance document </strong>for managing <strong>out-of-specification (OOS) results</strong> within the pharmaceutical industry. The guidance emphasizes a <strong>rigorous two-phase investigation</strong> to determine if a failure stems from a <strong>laboratory error</strong> or a deeper <strong>manufacturing flaw</strong>. <strong>Phase I</strong> focuses on the analyst’s immediate assessment of technical accuracy, while <strong>Phase II</strong> involves a full-scale review of production processes by the <strong>quality unit</strong>. Crucially, the sources warn against <strong>"testing into compliance,"</strong> noting that companies cannot simply retest a sample until it passes without a <strong>scientific root cause</strong> for the initial failure. Ultimately, the documentation underscores that <strong>maintaining scientific integrity</strong> and <strong>protecting patient safety</strong> must take precedence over the desire to release a product batch.</p>]]></description>
      <link>https://rss.com/podcasts/gxptraining/2509268</link>
      <enclosure url="https://content.rss.com/episodes/370070/2509268/gxptraining/2026_01_31_15_27_33_690b087a-bf0f-417f-a745-d1c2562a13df.mp3" length="16608162" type="audio/mpeg"/>
      <guid isPermaLink="false">71edb7ad-2562-47d3-b4cf-b90bb406d70d</guid>
      <itunes:duration>1037</itunes:duration>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:season>2026</itunes:season>
      <podcast:season>2026</podcast:season>
      <itunes:episode>1</itunes:episode>
      <podcast:episode>1</podcast:episode>
      <itunes:explicit>false</itunes:explicit>
      <pubDate>Sat, 31 Jan 2026 15:27:40 GMT</pubDate>
      <itunes:image href="https://media.rss.com/gxptraining/ep_cover_20260131_030116_4f01c92ff32beb4d6c88baf08ff6a4a6.jpg"/>
    </item>
  </channel>
</rss>